Posthypercapnic metabolic alkalosis

Electrolyte Disordersmedium

A 67-year-old man with hypertension and COPD on 2 L/min home oxygen presents with progressive lethargy and altered mental status 1 week after an upper respiratory infection. BP is 145/78 mm Hg, oxygen saturation 86% on 6 L/min, with diffuse bilateral wheezing. He is treated for a COPD exacerbation and started on BiPAP for hypercarbia, and his mental status improves over 48 hours. Arterial blood gas on admission and now: pH 7.27 and 7.55; PaCO₂ 81 and 40 mm Hg; bicarbonate 36 and 34 mEq/L. What is the most appropriate treatment for his current acid-base abnormality?

  1. A.Prescribe furosemide IV
  2. B.Prescribe acetazolamideCorrect
  3. C.Administer normal saline IV
  4. D.Decrease BiPAP tidal volume

Explanation

The most appropriate treatment is acetazolamide. On admission, this patient had acute-on-chronic respiratory acidosis with PaCO₂ 81 mm Hg and a bicarbonate of 36 mEq/L, reflecting chronic renal compensation for long-standing hypercapnia. BiPAP lowered PaCO₂ to 40 mm Hg within 48 hours, but the kidney needs days to excrete the retained bicarbonate, so the now-unopposed bicarbonate of 34 mEq/L produces a posthypercapnic metabolic alkalosis with a pH of 7.55. Severe alkalemia shifts the oxyhemoglobin dissociation curve to the left, reduces cerebral and coronary blood flow, lowers ionized calcium and potassium, predisposes to arrhythmias and seizures, and blunts respiratory drive, which can impair weaning. Acetazolamide inhibits proximal tubular carbonic anhydrase, producing bicarbonaturia that lowers serum bicarbonate within 24 to 48 hours. In a patient without volume or chloride depletion, it is the most direct treatment. Potassium should be monitored and repleted, because bicarbonaturia increases distal potassium losses. In ventilated COPD patients, acetazolamide reliably lowers bicarbonate, although the DIABOLO trial did not show a reduction in duration of ventilation, so its role is correction of significant alkalemia rather than routine use. Reducing ventilatory support to allow PaCO₂ to rise back toward his chronic baseline would correct the pH, but it reintroduces hypercapnia in a patient who has just recovered from hypercapnic encephalopathy. BiPAP is also a pressure-targeted mode without a set tidal volume. Normal saline corrects chloride-responsive alkalosis when volume depletion and chloride deficit maintain bicarbonate reabsorption. Nothing suggests volume depletion here, and the alkalosis is maintained by prior renal adaptation to hypercapnia rather than chloride deficiency; saline would add an unnecessary volume load. Furosemide would worsen the alkalosis through contraction of extracellular volume, chloride loss, and increased distal hydrogen and potassium secretion.

Why each option

A.
Furosemide causes contraction alkalosis, chloride loss, and increased distal acid secretion, so it would worsen rather than correct the alkalemia.
B.
Correct. Rapid correction of chronic hypercapnia leaves retained bicarbonate unopposed; acetazolamide induces bicarbonaturia and corrects posthypercapnic alkalosis in a patient who is not volume depleted.
C.
Saline treats chloride-responsive alkalosis from volume depletion; nothing suggests volume or chloride deficit here, so it adds unnecessary volume without addressing bicarbonate retention.
D.
Allowing PaCO₂ to rise reintroduces hypercapnia after recent hypercapnic encephalopathy, and pressure-targeted BiPAP has no set tidal volume to reduce.

Reference: Faisy C, JAMA 2016 (DIABOLO trial of acetazolamide in COPD); Galla JH, J Am Soc Nephrol 2000 (metabolic alkalosis)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Electrolyte Disorders questions

Browse other topics